Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：2
|
作者：
Piotrowska, Zofia [1 ]
Sequist, Lecia V. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期
关键词：
ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;
D O I：
10.1016/j.jtho.2017.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：419 / 421
页数：3
相关论文
共 50 条
  • [31] Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer
    Ayeni, Deborah
    Politi, Katerina
    Goldberg, Sarah B.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3818 - 3820
  • [32] Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer
    Wang, Caiyun
    Wang, Tao
    Lv, Dacheng
    Li, Ling
    Yue, Jinnan
    Chen, Hong-Zhuan
    Xu, Lu
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2357 - 2367
  • [33] New treatment strategy for patients with EGFR-mutant lung cancer
    Ninomiya, Takashi
    Takigawa, Nagio
    Toyooka, Shinichi
    Hotta, Katsuyuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER MANAGEMENT, 2013, 2 (06) : 505 - 516
  • [34] How to develop novel treatments for EGFR-mutant lung cancer
    Banna, Giuseppe Luigi
    Tiseo, Marcello
    FUTURE ONCOLOGY, 2015, 11 (17) : 2375 - 2378
  • [35] Enhancing apoptosis to improve the therapy of EGFR-mutant lung cancer
    Tanaka, Kosuke
    Han, Song
    Ganesan, Yogesh T.
    Hsieh, James J.
    Cheng, Emily H.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer
    Barber, Emily A.
    Reckamp, Karen L.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 4 - 7
  • [37] Role of tyrosine phosphorylation of β-catenin in EGFR-mutant lung cancer
    Fujii, Masanori
    Nakayama, Sohei
    Shimizu, Kohei
    Takei, Hisashi
    Ando, Mariko
    Heo, Eunyoung
    Kobayashi, Ikei
    Pan, Gilbert
    Inuzuka, Hiroyuki
    Kobayashi, Susumu
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Afatinib—new therapy option for EGFR-mutant lung cancer
    Helena A. Yu
    William Pao
    Nature Reviews Clinical Oncology, 2013, 10 : 551 - 552
  • [39] Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
    Pirazzoli, Valentina
    Takezawa, Ken
    de Stanchina, Elisa
    Pao, William
    Politi, Katerina
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [40] Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer
    Lee, Meng-Hsuan
    Hong, Shiao-Ya
    Kao, Yu-Rung
    Wu, Cheng-Wen
    CANCER RESEARCH, 2019, 79 (13)
12345